An Open-Label, Multicenter, Phase 1B/2 study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies
Study of RP1 in Organ Transplant Patients with Skin Cancer
Sponsor: Replimune, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU1155
U.S. Govt. ID: NCT04349436
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This trial is being done to look at the effects of RP1 in kidney, liver, heart, and lung transplant recipients with skin cancer. These effects could be good (for example, shrinking of tumors) or bad (called side effects). Researchers will study the effects and how long they last. This study is being done to find out how effective RP1 is in treating the cancer and how safe it is.
Investigator
Shaheer Khan, DO
Do You Qualify?
Are you at least 18 years old? Yes No
Have you had a kidney, liver, heart, or lung transplant? Yes No
Have you been diagnosed with skin cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE